1. Transarterial chemoembolisation plus stereotactic body radiotherapy as conversion therapy for large right lobe hepatocecullar carcinoma.
- Author
-
Lam, Tang‐yu, Wong, Wai‐man, Lee, Ching‐ching, and Cheung, Chin‐cheung
- Subjects
- *
CONVERSION therapy , *STEREOTACTIC radiotherapy , *SURVIVAL rate , *CARCINOMA , *PATIENTS' rights , *CHEMOEMBOLIZATION - Abstract
Huge right lobe hepatocecullar carcinoma (HCC) at presentation is not uncommon in Hong Kong. The aim of this study was to evaluate whether transarterial chemoembolisation (TACE) followed by stereotactic body radiotherapy (SBRT) can be used as a conversion therapy for huge right lobe HCC. We retrospectively reviewed two groups of patients with solitary huge right lobe HCC (defined as > = 10 cm in size) treated with direct surgery or conversion therapy (TACE + SBRT) first. From 2009 to 2014, 23 patients with huge right lobe HCC with resection done in our centre were reviewed. Eleven patients had direct surgery and 12 patients had received conversion therapy first. The mean tumour size for the conversion therapy group was significantly larger 13.9 cm versus 11.2 cm (p =.03). Patients in the conversion therapy group also had other unfavourable factors at presentation. Overall median survival for direct surgery group was 63 months while that of conversion therapy group was 40 months (p =.48). Operative time was 313 min for the direct surgery group versus 317 min for the conversion therapy group (p =.95). We concluded that TACE + SBRT can be a feasible conversion therapy for borderline resectable huge right lobe HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF